Latest Regulatory Filings News

Coronado Global Resources posted a $109.5 million net loss for Q3 2025 amid subdued metallurgical coal markets and announced a proposed refinancing deal with Stanwell Corporation to strengthen its financial position.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Savannah Goldfields Limited has explained the late filing of a director’s interest notice, attributing it to an oversight during an entitlement offer. The company affirms its compliance processes remain robust despite the delay.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

BPH Energy’s September quarter report highlights pivotal developments across its investees, from a critical judicial review in offshore petroleum to breakthroughs in AI medical devices and clean hydrogen production.